June 22, 2026 16:05 ET | Source: Centessa Pharmaceuticals plc
BOSTON and LONDON, June 22, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurological conditions, which entered into a definitive agreement on March 31, 2026 relating to its proposed acquisition by Eli Lilly and Company (“Lilly”), through a wholly owned subsidiary, today announced that the High Court of Justice of England and Wales has approved the proposal for Lilly to acquire Centessa for $38.00 in cash per share plus one non-transferable contingent value right (“CVR”) that entitles the holder to receive up to an aggregate of $9.00 subject to the achievement of three milestones, for a total transaction value of approximately $7.8 billion (the “Transaction”).
The Transaction is being implemented by way of a Court-sanctioned scheme of arrangement under English law (the “Scheme”).
Centessa is pleased to announce that the Court has today issued the Court Order sanctioning the Scheme.
Closing of the Transaction will occur and the Scheme will become effective upon the Court Order being delivered to the Registrar of Companies, which is expected to occur on June 24, 2026. The last day of trading of Centessa American Depositary Shares (“ADSs”) on Nasdaq is expected to be tomorrow, June 23, 2026, with trading in Centessa ADSs on Nasdaq being halted before the opening of trading on June 24, 2026.
Unless otherwise defined, terms used in this press release have the same meanings as set out in the definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission (the “SEC”) by Centessa on May 7, 2026.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients. We are pioneering a new class of potential therapies within our orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness, impaired attention, cognitive deficits and fatigue across neurological, neurodegenerative and neuropsychiatric disorders.
UK Takeover Code Does Not Apply
Centessa is not a company subject to regulation under the United Kingdom City Code on Takeovers and Mergers (the "UK Takeover Code"), therefore no dealing disclosures are required to be made under Rule 8 of the UK Takeover Code by shareholders of Centessa or Lilly.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended, including with respect to the Transaction. Such forward-looking statements include, but are not limited to, statements regarding: the Transaction; potential contingent consideration amounts; the parties' ability to satisfy the conditions to the consummation of the Transaction, including in connection with the expected timetable for the Transaction; and the anticipated occurrence, manner and timing of the closing of the Transaction. All statements other than statements of historical facts are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on current beliefs and expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements.
These risks and uncertainties include, but are not limited to: a condition to closing of the Transaction may not be satisfied (or waived); the ability of each party to consummate the Transaction; the closing of the Transaction might be delayed or not occur at all; the diversion of management time and attention from ongoing business operations and opportunities; the response of competitors to the Transaction; the effect of the Transaction on Centessa's operations and its relationships with its suppliers, business partners, management and employees, including its ability to attract and retain key personnel; the outcome of any legal proceedings that could be instituted against the parties to the Transaction; the risks inherent in drug research, development and commercialization; disruption in Centessa's plans and operations attributable to the Transaction; changes in Centessa's business during the period between announcement and closing of the Transaction; the effects of the Transaction on Centessa's share price; the risks related to non-achievement of any milestone and that holders of the CVRs will not receive any payments in respect of the CVRs; relationships with key third parties or governmental entities; regulatory changes and developments; and the impact of global macroeconomic conditions, including trade and other global disputes and interruptions, including related to tariffs, trade protection measures, and similar restrictions. For further discussion of these and other risks and uncertainties, see the “Risk Factors” section of Centessa’s Quarterly Report on Form 10-Q filed with the SEC on May 5, 2026, as well as discussions of potential risks, uncertainties and other important factors, in Centessa’s most recent filings with the SEC and in other filings that Centessa makes with the SEC in the future. There can be no assurance that the Transaction will be consummated in the anticipated timeframe or at all, that any event, change or other circumstance that could give rise to the termination of the definitive agreement for the Transaction will not occur, or that any product candidates will be approved on anticipated timelines or at all. All forward-looking statements in this press release are based on information available to Centessa as of the date of this press release. Centessa expressly disclaims any obligation to publicly update or revise the forward-looking statements, except as required by law.
Contact:
Kristen Sheppard, Esq.
Senior Vice President, Investor Relations & Corporate Communications [email protected]
www.centessa.com
Follow Centessa Pharmaceuticals on LinkedIn
Eli Lilly and Co (NYSE:LLY) said on Tuesday it will acquire Centessa Pharmaceuticals PLC (NASDAQ:CNTA) for $38 per share in cash, with a potential contingent value right worth up to $9 per share, valuing the deal at approximately $6.3 billion upfront and up to $7.8 billion including milestones.
The acquisition adds Centessa’s sleep-wake disorder pipeline, including its lead asset cleminorexton, to Lilly’s neuroscience business.
Cleminorexton is being evaluated in clinical trials for narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia.
Centessa shares surged about 45% in early trading on Tuesday, while Lilly shares rose roughly 2.9%.
BMO Capital reiterated an Outperform rating and a $1,300 price target on Eli Lilly shares following the acquisition announcement. The firm said the deal is positive for Lilly, noting the company is acquiring from a position of strength and diversifying its business ahead of any major loss of exclusivity events.
The deal highlights Lilly’s effort to broaden its portfolio beyond metabolic treatments and strengthen its presence in neuroscience.
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
The proposed transactions may contain terms that could limit superior competing offers.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)'s sale to Biogen Inc. for $41.00 per share in cash and a nontransferable contingent value right for the right to receive two payments of $2.00 per share each, contingent on certain annual global net sales thresholds being met for SYFOVRE. If you are an Apellis shareholder, click here to learn more about your legal rights and options.
Centessa Pharmaceuticals plc (NASDAQ: CNTA)'s sale to Eli Lilly and Company for $38.00 in cash per share plus one non-transferrable contingent value right entitling the holder to receive up to an aggregate of $9.00 subject to the achievement of certain milestones. If you are a Centessa shareholder, click here to learn more about your legal rights and options.
Allbirds, Inc.'s (NASDAQ: BIRD)'s sale of its intellectual property and certain other assets to American Exchange Group for $39 million. If you are an Allbirds shareholder, click here to learn more about your legal rights and options.
On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures and information, or other relief and benefits.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
One World Trade Center
85th Floor
New York, NY 10007
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com
Stocks are eyeing a strong March finish, with the Dow Jones Industrial Average (DJI) up 514 points. The Nasdaq Composite (IXIC) and S&P 500 Index (SPX) sport outsized leads of their own, with all three major indexes eyeing their best single-session gains since Feb. 6. Investors are brushing off elevated oil prices after President Donald Trump appeared willing to end the war with Iran, even if the Strait of Hormuz remained mostly shuttered.
Despite today's gains, all three benchmarks remain on track for severe monthly and quarterly losses. In fact, the Dow and S&P 500 are pacing for their worst months since September 2022 and their worst quarters since June 2022.
Nike stock making headway before earnings. Marvell's $2 billion AI partnership with Nvidia. Plus, pharma buyout buzz; earnings boost FDS; and Constellation's dismal forecast.
Centessa Pharmaceuticals PLC (NASDAQ:CNTA) stock is surging today, last seen 44.7% higher to trade at $39.90 on news that Eli Lilly (LLY) will acquire the company for $6.3 billion. Options traders are targeting CNTA in response, with 2,981 calls and 1,077 puts exchanged so far -- 19 times the volume typically seen at this point. Most active is the April 30 call, with positions being sold to open at the May 40 put. CNTA is eyeing its best day on record and earlier surged to a fresh all-time high of $40.26. In the last nine months, the stock has added 203.8%.
Factset Research Systems Inc (NYSE:FDS) stock is leading the SPX today, up 6.3% to trade at $217.43 at last check. This surge comes after the financial data and software giant reported better-than-expected fiscal-second quarter earnings and revenue. FDS is eyeing its fourth-straight win and best single-day percentage pop since June 2022. The shares are also eyeing a close above their 40-day moving average for the first time since January, but still carry a 24.2% deficit for 2026.
Meanwhile, Constellation Energy Corp (NASDAQ:CEG) stock is at the bottom of the SPX, last seen down 8.7% at $272.59, after the company issued a 2026 profit forecast that came in below expectations. CEG has been struggling to conquer resistance from the 80-day moving average since late February. Year to date, the energy stock has shed 22.7%.
Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- LLP is investigating Centessa (NASDAQ: CNTA) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Lilly.
Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.
In the transaction, Centessa stockholders will receive $38.00 per share in cash plus contingent value rights worth up to $9.00 per share. The contingent value rights entitle holders to receive up to three milestone payments: $2.00 upon U.S. FDA approval for narcolepsy type 2 treatment, $5.00 for idiopathic hypersomnia approval, and $2.00 for any indication approval before January 1, 2030. All approvals must occur within five years of transaction closing.
Centessa insiders will receive substantial benefits as part of change of control arrangements.
The transaction agreement unreasonably limits competing transactions for Centessa by imposing a significant penalty if Centessa accepts a competing bid. We are investigating the conduct of the Centessa board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Eli Lilly has agreed to acquire Centessa Pharmaceuticals in a deal valued at up to $7.8 billion, marking a significant expansion of the drugmaker’s neuroscience portfolio into sleep medicine.
Under the terms announced Tuesday, Lilly will pay $38 per share in cash upfront, valuing Centessa at approximately $6.3 billion.
The offer represents a 38% premium to Centessa’s Monday closing price of $27.58.
Shareholders will also receive nontransferable contingent value rights worth up to an additional $9 per share, tied to future regulatory approvals of Centessa’s drug candidates.
The total potential consideration brings the deal value to $47 per share or about $7.8 billion.
The transaction is expected to close in the third quarter, subject to regulatory approval.
Lilly’s shares rose 2.75% following the announcement, while Centessa’s US-listed ADR surged 45%, reflecting investor optimism about the strategic fit and future potential of the pipeline.
The acquisition centers on Centessa’s experimental drug portfolio targeting excessive daytime sleepiness, including narcolepsy and idiopathic hypersomnia.
These conditions impair the ability to stay awake during the day and are part of a broader category of neurological disorders.
Centessa’s lead candidate, cleminorexton, has demonstrated what Lilly described as a potential best-in-class profile in Phase 2a studies.
Another candidate, ORX142, is also part of the agreement, with milestone payments tied to approvals from the US Food and Drug Administration.
The therapies belong to a new class of drugs known as orexin agonists, which target the brain’s sleep-wake regulation system. The approach is drawing increasing interest across the pharmaceutical industry.
“Orexin receptor biology represents one of the most compelling mechanistic opportunities in neuroscience as a direct intervention on the master switch of the sleep-wake cycle,” Dr. Carole Ho, president of Lilly Neuroscience, said in a statement. “Centessa has assembled a portfolio with the breadth and depth to improve wakefulness across a broad array of indications.”
Beyond narcolepsy, these drugs may have applications in conditions such as Alzheimer’s disease and depression, where drowsiness is a common symptom.
Centessa is not expected to be first to market in the orexin agonist category.
A competing treatment from Takeda is currently under FDA review and could receive approval later this year.
Analysts estimate the market for orexin-based treatments could reach between $15 billion and $20 billion if roughly a quarter of eligible patients seek treatment.
Wider adoption across additional neurological conditions could further expand that opportunity.
Despite promising mid-stage data, Centessa’s lead drug is not expected to gain approval until 2028, according to analyst estimates. However, early results suggest it could emerge as a best-in-class option.
The deal underscores Lilly’s broader strategy of reinvesting proceeds from its successful obesity and diabetes drugs, including Zepbound and Mounjaro, into new therapeutic areas.
It also follows a series of recent acquisitions. Earlier this year, Lilly announced plans to acquire Orna Therapeutics for up to $2.4 billion and Ventyx Biosciences for about $1.2 billion.
With the Centessa deal, Lilly is deepening its presence in neuroscience, building on a legacy that includes blockbuster treatments such as Prozac and more recent Alzheimer’s therapy Kisunla.
Centessa Pharmaceuticals PLC (NASDAQ:CNTA) shares are surging today, last seen 44.4% higher to trade at $39.90 on news that Eli Lilly (LLY) will acquire the company for $6.3 billion. The move is part of the former's plans to diversify its metabolic portfolio with sleep disorder treatments.
Analysts chimed in on the update, with Needham and B. Riley downgrading CNTA to "hold" and "neutral," respectively, from "buy." Piper Sandler cut its rating to "neutral" from "overweight." Analysts were bullish coming into today, with 16 of the 17 in coverage sporting "buy" or better ratings.
Options traders are targeting CNTA, too, with 3,467 calls and 2,687 puts traded so far -- 11 times the volume typically seen at this point. Most active is the April 30 call, followed by the December 22.50 puts.
CNTA is headed for its best day on record and earlier scored an all-time high of $40.26. The shares are staging a bounce off the rising 40-day moving average, and now sport a more than 203% nine-month lead.
Lilly to gain ownership of Centessa's OX2R agonist pipeline designed to improve outcomes across sleep-wake disordersCentessa’s OX2R agonist pipeline was jointly discovered by Nxera and Centessa, and Nxera retains a material economic interest in its future development and commercialization Tokyo, Japan and Cambridge, UK, 1 April 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner, Centessa Pharmaceuticals Limited (“Centessa”), has announced that it entered into a definitive agreement regarding its acquisition by Eli Lilly and Company (“Lilly”) on 31 March 2026 (US local time).
Please refer to the full text of Centessa’s news release at the link below:
https://investors.centessa.com/press-releases/
Centessa's orexin receptor 2 (OX2R) agonist series, cleminorexton (formerly ORX750), ORX142 and ORX489, were jointly discovered by Centessa and Nxera scientists under a collaboration in which Centessa had access to Nxera's proprietary NxStaR™ technology. Nxera is entitled to receive certain milestone payments and royalties in relation to all of these OX2R agonists, and the contractual terms governing those rights are unaffected by this proposed transaction. In addition, Nxera holds an equity interest in Centessa.
Christopher Cargill, President and CEO of Nxera Pharma, commented: “We congratulate Centessa on its success to date advancing its OX2R agonist pipeline into clinical development and demonstrating best-in-class potential to bring improved outcomes to people with sleep-wake disorders. It will be exciting to see these novel candidates advance further under Lilly’s guidance.
“This is yet another example of a world-leading pharmaceutical company acquiring potential medicines with broad therapeutic application that originated in our research laboratory in Cambridge, United Kingdom, and a further demonstration of Nxera's rich heritage in CNS drug discovery. Potential medicines born from our NxStaR™ technology and NxWave™ GPCR structure-based drug design platform are now progressing toward late-stage clinical development with several of the world's leading pharmaceutical companies. The quality of our science, and the continued external validation of our platform, has never been stronger.
“We carry this momentum forward as we apply the same capabilities to our emerging, wholly owned metabolic and rare endocrine disease pipeline, targeting some of the largest areas of global unmet medical need. Nxera remains committed to delivering new treatment options to patients around the world through innovative science.”
Nxera has a separate multi-target collaboration with Lilly, entered in 2022, to leverage Nxera’s NxWave™ GPCR-focused structure-based drug design capabilities and Lilly’s extensive development, commercialization and therapeutic area expertise in metabolic diseases. The collaboration remains ongoing. Under the terms of that separate agreement, Nxera is eligible to receive development and commercial milestones totalling up to US$694 million, plus tiered royalties on global sales.
–END–
About Nxera Pharma
Nxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. The Company has built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high-value, large and growing market and those in the broader APAC region. In addition, the Company is advancing an extensive pipeline internally and in partnership with leading pharma and biotech companies powered by its unique NxWave™ GPCR structure-based drug discovery platform. Nxera Pharma operates at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565).
For more information, please visit www.nxera.life
LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma
Enquiries:
Nxera – Media and Investor Relations
Shinya Tsuzuki, VP, Head of Investor Relations
Maya Bennison, Communications Manager
+81 (0)3 5210 3399 | +44 (0)1223 949390 |[email protected]
MEDiSTRAVA (for International Media)
Mark Swallow, Frazer Hall, Erica Hollingsworth
+44 (0)203 928 6900 | [email protected]
Forward-looking statements
This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group’s actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Shares of Centessa Pharmaceuticals (CNTA 0.14%) surged on Tuesday after the drugmaker struck a deal to be acquired by Eli Lilly (LLY 0.51%) for as much as $7.8 billion.
Image source: Getty Images.
An enticing offer for Centessa's investors Under the terms of the deal, Lilly would purchase Centessa for $38 per share in cash. That's a premium of nearly 38% to the healthcare stock's closing price on Monday.
Centessa's shareholders would also receive a non-transferrable contingent value right, which could be valued at up to $9 per share if the pharmaceutical company's investigational drugs achieve certain regulatory milestones.
The transaction is projected to close in the third quarter, subject to shareholder and regulatory approval.
Today's Change
(
-0.14
%) $
-0.06
Current Price
$
39.70
Advancing neuroscience Centessa is developing a novel class of drugs, known as orexin receptor 2 (OX2R) agonists, to treat daytime sleepiness and other neurological conditions. Its most promising experimental drug, cleminorexton, showed best-in-class potential in Phase 2 clinical studies for severe sleep disorders, including narcolepsy and idiopathic hypersomnia.
"Orexin receptor biology represents one of the most compelling mechanistic opportunities in neuroscience as a direct intervention on the master switch of the sleep-wake cycle," Lilly executive Carole Ho said. "Centessa has assembled a portfolio with the breadth and depth to improve wakefulness across a broad array of indications."
Blockbuster potential Lilly is wisely using the windfall from its highly successful GLP-1 drugs Mounjaro and Zepbound to diversify its development pipeline. Centessa's experimental therapies could become top sellers in a potential $20 billion market for treatments for severe sleep conditions, according to investment bank Oppenheimer.
Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Centessa Pharmaceuticals Plc. The Motley Fool has a disclosure policy.
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Centessa Pharmaceuticals plc (NasdaqGS: CNTA) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Centessa will receive $38.00 in cash per share plus one non-transferrable contingent value right entitling the holder to receive up to an aggregate of $9.00 subject to the achievement of certain milestones. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ([email protected]) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-cnta/ to learn more.
To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.
Pre-Market Stock Futures: Futures are trading higher after an explosive rally on Tuesday, sparked by the President’s comments that he wants to end the war soon. While this is hardly the final straw for the war, it appears that President Trump, who is finally getting some support from NATO members and Persian Gulf allies in the fight against Iran and its paid proxies, may be making some progress. Add in the fact that Iran’s infrastructure and weaponry have been devastated, and many of the military and Revolutionary Guard leaders have been killed. Toss in the massive short interest, and it all adds up to Tuesday’s huge rally, with the Nasdaq as the big winner, closing up a stunning 3.83% at 21,590, and the small-cap Russell 2000 not far behind, finishing the session at 2,496, up 3.41%. The S&P 500 closed Tuesday at 6,528, up 2.91%, and the Dow Jones Industrial finished the clean sweep of winners, closing at 46,341, up 2.49%.
Treasury Bonds: Yields were lower across the curve, except at the very short T-bills and the long end, as buyers returned, as they did on Monday. Some of the same reasons we have cited recently for bond prices rising (and yields falling) were again driven by safe-haven demand amid intensified Middle East conflict. Investors shifted from fears of inflation to concerns about slower global growth, prompting a “bull steepening” of the yield curve and a rebound after a month of heavy selling.
Oil and Gas: Prices were mixed across the energy complex, which experienced severe intraday volatility, initially dropping on reports of a potential de-escalation in Iran but remaining supported by lingering anxieties over supply disruptions, particularly after a tanker was hit near Dubai. Toss in futures contract expirations, and the stage was set for a crazy end to the quarter. Brent Crude closed up 4.94% at $118.30, while West Texas Intermediate closed down at $101.50, down 1.33%. Natural Gas finished the day at $2.84, dowm 0.10%.
Gold: The precious metals joined in on the rally as gold, which has traded in a tight range for the better part of the first quarter, had an impressive day, closing trading up a whopping 3.49% at $4,667, while Silver really had some momentum buying and was last seen on Tuesday at $75, up a strong 7.18%. Wall Street analysts attributed the big moves higher to the recent decline to market overreaction, as investors moved to buy the dip. This rebound suggests a resilient bullish sentiment, even as the market grapples with rising oil prices, inflationary pressure, and weakening consumer confidence.
Crypto: The cryptocurrency market endured a turbulent session marked by sharp price swings but demonstrated solid resilience, holding firm at key support levels amid heightened geopolitical tensions. Developments heavily influenced risk sentiment across the broader crypto space, as traders responded swiftly to shifting headlines. Bitcoin led the volatility, surging to an intraday high of $68,300 in early trading after reports emerged of potential peace negotiations between Iran and Israel briefly lifted market optimism. However, the rally proved short-lived, with the crypto giant retracing to a consolidation range of $67,000–$67,800 as uncertainty resurfaced and profit-taking set in. The speed of the reversal underscored how sensitive the market remains to geopolitical developments, with algorithmic trading and leveraged positions amplifying the intraday swings. At 8 AM EDT, Bitcoin was trading at $68,680 while Ethereum was quoted at $2,135.
24/7 Wall St. reviews dozens of analyst research reports daily to identify new investment ideas for both investors and traders. Some of these daily analyst calls cover stocks to buy. Other calls cover stocks to sell or avoid. Remember that no single analyst call should ever be used as a basis to buy or sell a stock.
Here are some of the top Wall Street analyst upgrades, downgrades, and initiations seen on Wednesday, April 1, 2026.
Upgrades: Formula One Group (NASDAQ: FWONK | FWONK Price Prediction) was raised to Buy from Neutral at Bank of America, which has a $105 price target for the shares. Rivian Automotive Inc. (NASDAQ: RIVN) was upgraded to Neutral from Underperform at DA Davidson, with a $14 target price. United Health Group Inc. (NYSE: UNH) was upgraded to Outperform from Market Perform at Raymond James, which posted a $330 target price objective. Walt Disney Company (NYSE: DIS) was raised to Outperform from Market Perform at Raymond James, which has a $115 target for the entertainment giant. Wells Fargo & Company (NYSE: WFC) was upgraded to Buy from Hold at HSBC, with a $94 target price. Downgrades:
Apellis Pharmaceutical Inc. (NASDAQ: APLS) was downgraded to Hold from Buy at Stifel with a $41 target price as Biogen is acquiring the company. Centessa Pharmaceuticals Inc. (NASDAQ: CNTA) was downgraded to Market Perform from Outperform at Leerink, with a $40 target, as Eli Lilly is acquiring the company. First Citizens Bancshares Inc. (NASDAQ: FCNCA) was cut to Neutral from Overweight at JPMorgan, which dropped the target price for the shares to $2,200 from $2,450. Nike Inc. (NYSE: NKE) was downgraded to Neutral from Overweight at JPMorgan, which slashed the target price for the sports apparel and shoe giant to $52 from $86. PPG Industries Inc. (NYSE: PPG) was downgraded to Neutral from Buy at Citigroup, which trimmed the target price for the stock to $113 from $132. Initiations: Boeing Company (NYSE: BA) was initiated with an Overweight rating at Wells Fargo, which has a $250 target price for the aerospace giant.
Datadog Inc. (NASDAQ: DDOG) was started with a Buy rating at Benchmark, with a $150 target price. Northrop Grumman Corp. (NYSE: NOC) was started with an Overweight rating at Wells Fargo, with an $800 target price objective. Rocket Lab Corp. (NASDAQ: RKLB) was initiated with an Equal Weight rating at Wells Fargo, with a $60 target price. ServiceNow Inc. (NYSE: NOW) was initiated with a Buy rating at Benchmark with a $125 target price.
Key Takeaways Eli Lilly will buy Centessa for $6.3B upfront, with total value up to $7.8B including CVR payouts.LLY gains OX2R agonist pipeline, led by cleminorexton in mid-stage trials for narcolepsy and IH.Centessa surged 44% after the deal, which supports Lilly's broader pipeline diversification strategy. Eli Lilly (LLY - Free Report) announced that it has entered into a definitive agreement to acquire U.K.-based Centessa Pharmaceuticals (CNTA - Free Report) . Per the terms, the pharma giant will acquire all outstanding shares (including American Depositary Shares) of CNTA for $38 per share in cash, aggregating to about $6.3 billion.
In addition, Centessa’s shareholders will receive one non-tradable contingent value right (CVR) per share. This CVR entitles holders to an additional cash payment of up to $9 per share, contingent on achieving FDA approvals of either of its two pipeline drugs (cleminorexton and ORX142) across narcolepsy type II and idiopathic hypersomnia (IH) indications over the next few years. Including the CVR, the total potential deal value reaches approximately $7.8 billion.
Post this acquisition, Lilly will add Centessa’s pipeline of orexin receptor 2 (OX2R) agonists for treating people with sleep-wake disorders. This includes the lead drug, cleminorexton (formerly ORX750), which is being evaluated in a mid-stage study for two types of narcolepsy (type I and II) and IH. Last year, CNTA reported initial results from this study, which Lilly describes as demonstrating “a potential best-in-class profile” for the drug.
Another drug in Centessa’s pipeline is ORX142, which is being evaluated in an early-stage study for neurological and neurodegenerative disorders. A third candidate, ORX489, is currently in preclinical development and is being developed for neuropsychiatric disorders.
The transaction, which was approved by the board of directors of both companies, is expected to be closed in the third quarter.
CNTA & LLY Stock PerformanceFollowing this news on Tuesday, shares of Centessa increased 44%, while Lilly rose about 4%.
Year to date, CNTA stock has risen 59%, while that of LLY has lost more than 14%. During the same time frame, the industry has gained 1%.
Image Source: Zacks Investment Research
How Does CNTA Buyout Benefit LLY?Unlike some of its peers, such as Bristol Myers and Sanofi, which are under pressure from investors to pursue deals for new drugs, Lilly’s top line continues to reach new heights. The tremendous success of GLP-1 drugs, Mounjaro (for diabetes) and Zepbound (for obesity), has helped make it the first pharmaceutical company to reach a market capitalization of $1 trillion.
The rationale behind the deal is clear — Lilly intends to strategically diversify its pipeline across therapeutic areas. Recent approvals in immunology (Omvoh and Ebglyss), oncology (Jaypirca) and neuroscience (Kisunla) highlight Lilly’s intent to diversify beyond obesity and diabetes. A potential deal for Centessa fits this trend.
The transaction benefits CNTA, which lacks the commercial infrastructure and global scale required to bring advanced therapies to market, areas where LLY is already well established.
Once closed, this will be the third acquisition deal signed by Lilly so far this year. Earlier in January, it signed a $1.2 billion deal to buy Ventyx Biosciences to deepen its exposure to oral small-molecule therapies targeting inflammatory-mediated diseases. In February, LLY announced its intent to acquire Orna Therapeutics for up to $2.4 billion, which will add a broad portfolio of in vivo CAR-T pipeline.
Recent M&A Transactions in the Pharma SpaceWhile broader macroeconomic concerns — including Trump-era tariffs and leadership shifts at the FDA — have weighed on deal-making last year, Big Pharma continues to pursue strategic assets in key growth areas.
Recently, Biogen (BIIB - Free Report) announced its intent to acquire Apellis Pharmaceuticals for an upfront cash payment of about $5.6 billion to strengthen its immunology and rare disease portfolio. Through this transaction, BIIB intends to add two FDA-approved therapies — Empaveli and Syfovre. While Empaveli is approved for paroxysmal nocturnal hemoglobinuria (PNH) and two rare kidney diseases, Syforve is indicated for geographic atrophy. Biogen expects to close this deal in the second quarter of 2026.
Gilead Sciences (GILD - Free Report) is another company that has been involved in an acquisition spree since the start of this year. Last month, GILD entered into a deal worth $2.2 billion to acquire Ouro Medicines to strengthen its push into innovative therapies for autoimmune diseases. In February, Gilead announced its intent to acquire the clinical-stage biotechnology company Arcellx for an implied equity value worth $7.8 billion to boost its oncology portfolio.
These transactions highlight Big Pharma's continued interest in small biotechs with promising and innovative assets.
LLY & CNTA Zacks RankBoth Eli Lilly and Centessa Pharmaceuticals currently carry a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
, /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Centessa Pharmaceuticals plc (NASDAQ: CNTA) related to its sale to Eli Lilly and Company. Under the terms of the proposed transaction, Centessa shareholders are expected to receive $38.00 per share in cash and one non-transferable contingent value right entitling the holder to receive up to an aggregate of $9.00 subject to the achievement of certain milestones. Is it a fair deal?
Click here for more info https://monteverdelaw.com/case/centessa-pharmaceuticals-plc/. It is free and there is no cost or obligation to you.
NOT ALL LAW FIRMS ARE EQUAL. Before you hire a law firm, you should talk to a lawyer and ask:
Do you file class actions and go to Court? When was the last time you recovered money for shareholders? What cases did you recover money in and how much? About Monteverde & Associates PC
Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court.
No one is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.
Contact:
Juan Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4740
New York, NY 10118
United States of America
[email protected]
Tel: (212) 971-1341
Attorney Advertising. (C) 2026 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $40.00 and last traded at $40.0980, with a volume of 3519760 shares trading hands. The stock had previously closed at $27.58.
Trending Headlines about Centessa Pharmaceuticals Here are the key news stories impacting Centessa Pharmaceuticals this week:
Positive Sentiment: Eli Lilly agreed to acquire Centessa in a deal worth up to $7.8 billion (initial $38.00/share cash plus contingent value rights), which creates a takeover premium and is the primary driver of the stock’s upward move. Eli Lilly to buy Centessa Pharma Positive Sentiment: Leerink Partners reaffirmed a “market perform” rating and raised its price target to $40.00, a small upward revision that supports the view the deal price is appropriate. Leerink raises price target Neutral Sentiment: Unusual options activity: earlier spikes in call buying and, more recently, a large surge in put purchases (10,659 puts) signal mixed positioning—some traders betting on deal completion/arb, others hedging or speculating on downside. (No single article link) Negative Sentiment: Multiple brokerages downgraded CNTA (Needham, Wolfe Research, Stephens), citing valuation or deal-related uncertainty — analyst downgrades can weigh on momentum despite the takeover premium. Needham downgrades Negative Sentiment: Several law firms and shareholder groups have announced investigations into whether the sale process and price are fair (Monteverde, Kahn Swick & Foti, Ademi, Halper Sadeh). Potential litigation or challenges to the transaction could delay closing or pressure the spread between market price and deal consideration. Shareholder investigation announced Negative Sentiment: Recent quarterly results missed EPS estimates (reported ($0.48) vs. consensus ($0.38)), underscoring ongoing clinical and execution risks outside the transaction context. Centessa earnings miss Wall Street Analyst Weigh In Several research firms recently commented on CNTA. Stephens cut Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Truist Financial boosted their price target on Centessa Pharmaceuticals from $33.00 to $38.00 and gave the company a “buy” rating in a research note on Thursday, January 29th. TD Cowen restated a “buy” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 14th. Piper Sandler reaffirmed an “overweight” rating on shares of Centessa Pharmaceuticals in a research report on Friday, January 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $40.00.
Read Our Latest Analysis on CNTA
Centessa Pharmaceuticals Stock Performance The company has a market capitalization of $5.82 billion, a price-to-earnings ratio of -21.78 and a beta of 1.25. The company has a 50 day moving average price of $26.62 and a 200 day moving average price of $25.35. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.57 and a current ratio of 10.56.
Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) last announced its quarterly earnings results on Monday, April 6th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.10). Equities research analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current fiscal year.
Insider Transactions at Centessa Pharmaceuticals In related news, insider Gregory M. Weinhoff sold 73,196 shares of the stock in a transaction on Friday, March 13th. The stock was sold at an average price of $26.33, for a total value of $1,927,250.68. Following the transaction, the insider directly owned 65,925 shares in the company, valued at $1,735,805.25. This trade represents a 52.61% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Karen M. Anderson sold 120,029 shares of Centessa Pharmaceuticals stock in a transaction on Friday, March 13th. The shares were sold at an average price of $26.25, for a total transaction of $3,150,761.25. Following the completion of the sale, the insider directly owned 62,085 shares of the company’s stock, valued at approximately $1,629,731.25. The trade was a 65.91% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 349,073 shares of company stock valued at $9,429,412 over the last ninety days. 7.09% of the stock is owned by company insiders.
Institutional Inflows and Outflows A number of hedge funds have recently made changes to their positions in the business. Avoro Capital Advisors LLC increased its position in shares of Centessa Pharmaceuticals by 116.2% during the third quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company’s stock worth $262,096,000 after acquiring an additional 5,808,080 shares in the last quarter. EcoR1 Capital LLC lifted its position in Centessa Pharmaceuticals by 466.4% in the 4th quarter. EcoR1 Capital LLC now owns 3,115,000 shares of the company’s stock valued at $77,906,000 after acquiring an additional 2,565,000 shares in the last quarter. Braidwell LP bought a new position in Centessa Pharmaceuticals in the 4th quarter valued at about $54,730,000. Federated Hermes Inc. acquired a new position in Centessa Pharmaceuticals during the 3rd quarter valued at about $42,429,000. Finally, Maverick Capital Ltd. acquired a new position in Centessa Pharmaceuticals during the 4th quarter valued at about $41,110,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.
Centessa Pharmaceuticals Company Profile (Get Free Report)
Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.
Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.
Recommended Stories Five stocks we like better than Centessa Pharmaceuticals Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEHoneywell International Inc. (NASDAQ:HON) Sees Large Growth in Short Interest
NEXT HEADLINE »Short Interest in S&P Global Inc. (NYSE:SPGI) Declines By 15.1%
MILWAUKEE, April 07, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Centessa (NASDAQ: CNTA) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Lilly.
Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.
In the transaction, Centessa stockholders will receive $38.00 per share in cash plus contingent value rights worth up to $9.00 per share. The contingent value rights entitle holders to receive up to three milestone payments: $2.00 upon U.S. FDA approval for narcolepsy type 2 treatment, $5.00 for idiopathic hypersomnia approval, and $2.00 for any indication approval before January 1, 2030. All approvals must occur within five years of transaction closing.
Centessa insiders will receive substantial benefits as part of change of control arrangements.
The transaction agreement unreasonably limits competing transactions for Centessa by imposing a significant penalty if Centessa accepts a competing bid. We are investigating the conduct of the Centessa board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
The proposed transactions may contain terms that could limit superior competing offers.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)'s sale to Biogen Inc. for $41.00 per share in cash and a nontransferable contingent value right for the right to receive two payments of $2.00 per share each, contingent on certain annual global net sales thresholds being met for SYFOVRE. If you are an Apellis shareholder, click here to learn more about your legal rights and options.
Centessa Pharmaceuticals plc (NASDAQ: CNTA)'s sale to Eli Lilly and Company for $38.00 in cash per share plus one non-transferrable contingent value right entitling the holder to receive up to an aggregate of $9.00 subject to the achievement of certain milestones. If you are a Centessa shareholder, click here to learn more about your legal rights and options.
Kezar Life Sciences, Inc. (NASDAQ: KZR)'s sale to Aurinia Pharmaceuticals Inc. for $6.955 in cash per share and one non-transferable contingent value right. If you are a Kezar shareholder, click here to learn more about your legal rights and options.
On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures and information, or other relief and benefits.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
One World Trade Center
85th Floor
New York, NY 10007
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com
Pre-Market Stock Futures: Futures are trading lower this morning after negotiations with Iran failed over the weekend, and President Trump indicated the U.S. will block the Strait of Hormuz. This comes as we get set to start the first-quarter earnings season this week, as the major money-center banks and brokerage firms begin to report results today and tomorrow. The stock market ended last week higher, but it was a grind, with big swings throughout. When trading ended Friday, the market posted its best week since November. All the major indices finished Friday lower, except the Nasdaq, which closed at 22,902, up 0.35%. The Dow Jones Industrials were the loss leader on Friday, closing down 0.56% to finish at 47,916, while the Russell 2000 was last seen at 2,630, down 0.22%. The venerable S&P 500 almost broke even by the close, finishing Friday’s session down just 0.11% at 6,816.
Treasury Bonds: After a solid week for the Treasury market, sellers returned on Friday as yields rose across the entire curve, driven by persistent worries about inflation and perceived growing geopolitical instability in the Middle East, with oil-driven inflation fears continuing to pressure the market. Markets are adjusting to a more hawkish Federal Reserve, as traders price in higher interest rates that lower the value of existing bonds. Plus, there is a major issue for the bond market, given the mounting inflation in recent reports, that there could be no interest rate cuts in 2026. The 30-year-long bond closed Friday at 4.91%, while the benchmark 10-year note closed at 4.32%.
Oil and Gas: After a wild week across the energy complex, oil finished in positive territory for consumers, as both major benchmarks finished lower on the day, trading below the pivotal and psychological $100 level. Brent Crude closed Friday at $94.29, down 1.60%, while West Texas Intermediate finished the week at $96.57, down 1.33%. Natural gas also finished the day and the week lower, closing at $2.65, down 0.82%.
Gold: The precious metals complex, like all the other major sectors, finished a volatile week on a quieter note on Friday. Gold closed the session at $4,747, down 0.38%, while Silver closed modestly higher at $75.76, up 0.55%.
Crypto: Crypto markets traded in a “risk-off” mode on Friday, with Bitcoin holding above $72,000 as investors braced for inflation data that came in higher than expected. The market saw a tentative recovery following a broader corrective phase, with Ethereum holding just above key support levels while trading above the 50-day exponential moving average. The Cryptocurrency arena remains fragile and cautious as market participants analyze March’s hot Consumer Price Index (CPI) data, which indicated mounting inflationary pressure. At 7 AM EDT, Bitcoin was trading at $70,825, while Ethereum was quoted at $2, 184.
24/7 Wall St. reviews dozens of analyst research reports daily to identify new investment ideas for both investors and traders. Some of these daily analyst calls cover stocks to buy. Other calls cover stocks to sell or avoid. Remember that no single analyst call should ever be used as a basis to buy or sell a stock.
Here are some of the top Wall Street analyst upgrades, downgrades, and initiations seen on Monday, April 13, 2026.
Upgrades: Bilibili Inc. (NASDAQ: BILI) | BILI Price Prediction was upgraded to Overweight from Equal Weight at Morgan Stanley, which raised the target price to $31 from $25. Constellation Brands Inc. (NYSE: STZ) was upgraded to Buy from Hold at TD Cowen, which raised the price target for the stock to $190 from $142. CoreWeave (NASDAQ: CRWV) was upgraded by Macquerie to Outperform from Neutral, which raised the target price for the stock to $125 from $90. Starbucks Corp. (NASDAQ: SBUX) was raised to Hold from Underperform at Jefferies, which boosted the target price for the ubiquitous coffee retailer to $92 from $86. T-Mobile US Inc. (NASDAQ: TMUS) was upgraded to Overweight from Sector Weight at KeyBanc, with a $260 target price objective. Downgrades: Best Buy Inc. (NYSE: BBY) was double downgraded to Sell from Buy at Goldman Sachs, which lowered the price target for the retailer to $59 from $76. Centessa Pharmaceuticals Inc. (NASDAQ: CNTA) was downgraded to Hold from Buy at Truist with a $38 target price. This is the amount Eli Lilly is paying to purchase the company. Hewlett Packard Enterprise Co. (NYSE: HPE) was downgraded to Outperform from Strong Buy at Raymond James, which trimmed the target price for the legacy tech giant to $29 from $30. Nebius Group NV (NASDAQ: NBIS) was downgraded to Hold from Buy at Freedom Capital, which raised the target price for the stock to $154 from $108. Nike Inc. (NYSE: NKE) was downgraded to Hold from Buy at HSBC, which slashed the target price for the sporting apparel and shoe giant to to $48 from $90. Initiations: Adobe Inc. (NASDAQ: ADBE) was initiated with a Neutral rating at BTIG, with no price target posted.
Credo Technology Group Holding Ltd. (NASDAQ: CRDO) was initiated with a Buy rating at Jefferies, which has set a $175 target price for the company. Johnson Controls Inc. (NYSE: JCI) was initiated with an In Line rating at Evercore ISI, with a $155 target price. Rollins Inc. (NYSE: ROL) was started with a Hold rating at Loop Capital, which has set a $56 target price for the shares. Tempus AI Inc. (NASDAQ: TEM) was started with an Underperform rating at Jefferies, with a $35 price target.
B. Metzler seel. Sohn & Co. AG purchased a new position in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 38,432 shares of the company’s stock, valued at approximately $961,000.
A number of other large investors also recently added to or reduced their stakes in CNTA. TD Waterhouse Canada Inc. purchased a new position in Centessa Pharmaceuticals in the 4th quarter worth approximately $25,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Centessa Pharmaceuticals by 26.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company’s stock worth $117,000 after purchasing an additional 979 shares in the last quarter. DNB Asset Management AS purchased a new position in Centessa Pharmaceuticals in the 3rd quarter worth approximately $218,000. GSA Capital Partners LLP purchased a new position in Centessa Pharmaceuticals in the 3rd quarter worth approximately $455,000. Finally, BNP Paribas Financial Markets lifted its holdings in Centessa Pharmaceuticals by 3,028.1% in the 2nd quarter. BNP Paribas Financial Markets now owns 34,972 shares of the company’s stock worth $460,000 after purchasing an additional 33,854 shares in the last quarter. 82.01% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes A number of research firms recently commented on CNTA. Stephens cut Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 31st. Leerink Partners downgraded Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and lifted their price objective for the stock from $36.00 to $40.00 in a research note on Wednesday, April 1st. B. Riley Financial downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Chardan Capital reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Centessa Pharmaceuticals in a research note on Friday, January 2nd. Finally, Lifesci Capital downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 1st. Four analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Centessa Pharmaceuticals has an average rating of “Hold” and an average target price of $40.70.
Read Our Latest Analysis on Centessa Pharmaceuticals
Centessa Pharmaceuticals Stock Performance NASDAQ:CNTA opened at $39.47 on Monday. The company has a debt-to-equity ratio of 0.21, a current ratio of 8.57 and a quick ratio of 8.57. Centessa Pharmaceuticals PLC Sponsored ADR has a 1 year low of $10.95 and a 1 year high of $40.26. The stock’s 50 day simple moving average is $31.71 and its two-hundred day simple moving average is $27.35. The company has a market cap of $5.89 billion, a price-to-earnings ratio of -26.85 and a beta of 1.25.
Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) last released its quarterly earnings data on Tuesday, March 31st. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.10). As a group, equities analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current fiscal year.
Insider Activity In other news, insider Iqbal J. Hussain sold 38,951 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $25.15, for a total transaction of $979,617.65. Following the transaction, the insider owned 57,645 shares of the company’s stock, valued at approximately $1,449,771.75. The trade was a 40.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Gregory M. Weinhoff sold 73,196 shares of the business’s stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $26.33, for a total value of $1,927,250.68. Following the transaction, the insider directly owned 65,925 shares in the company, valued at approximately $1,735,805.25. This represents a 52.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 349,073 shares of company stock valued at $9,429,412. 7.09% of the stock is currently owned by insiders.
About Centessa Pharmaceuticals (Free Report)
Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.
Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.
Featured Articles Five stocks we like better than Centessa Pharmaceuticals Want to see what other hedge funds are holding CNTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Free Report).
Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEDycom Industries, Inc. $DY Shares Sold by B. Metzler seel. Sohn & Co. AG
NEXT HEADLINE »Farther Finance Advisors LLC Takes $500,000 Position in United States Gasoline Fund LP $UGA
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Centessa Pharmaceuticals plc (NasdaqGS: CNTA) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Centessa will receive $38.00 in cash per share plus one non-transferrable contingent value right entitling the holder to receive up to an aggregate of $9.00 subject to the achievement of certain milestones. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ([email protected]) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-cnta/ to learn more.
To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
The proposed transactions may contain terms that could limit superior competing offers.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Centessa Pharmaceuticals plc (NASDAQ: CNTA)'s sale to Eli Lilly and Company for $38.00 in cash per share plus one non-transferrable contingent value right entitling the holder to receive up to an aggregate of $9.00 subject to the achievement of certain milestones. If you are a Centessa shareholder, click here to learn more about your legal rights and options.
Whitestone REIT (NYSE: WSR)'s sale to Ares Management Corporation for $19.00 per share or unit. If you are a Whitestone shareholder, click here to learn more about your legal rights and options.
Green Dot Corporation (NYSE: GDOT)'s sale to Smith Ventures and CommerceOne Financial Corporation for $8.11 in cash and 0.2215 shares of a new publicly traded bank holding company for each share of Green Dot. If you are a Green Dot shareholder, click here to learn more about your rights and options.
On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures and information, or other relief and benefits.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
One World Trade Center
85th Floor
New York, NY 10007
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com
Proven Chief Medical Officer at several publicly listed and clinical-stage oncology companies with successful track record developing multiple modalities including radiotherapies from preclinical through global approvals across hematologic malignancies and solid tumors Played a leading role in clinical development and worldwide approvals of Erbitux® at Merck KGaA leading to its blockbuster status Led clinical development as CMO of NBE Therapeutics which was acquired by Boehringer Ingelheim for $1.4 billion, and most recently CMO of radiotherapy company Full-Life Technologies Timely key hire with Dr. Heeger's operational rigor and clinical expertise expected to elevate development of Actimab-A, ATNM-400, and Iomab-ACT as Actinium advances toward key data readouts and expanded clinical trials in 2H:2026 , /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced the appointment of Steffen Heeger, MD, MSc, as Chief Medical Officer. Dr. Heeger brings a rare combination of radiotherapy expertise, global oncology drug development leadership, and public-company experience. Over his career, he has translated multiple programs from IND submission through global clinical approval in the US, EU, and Japan including the blockbuster Erbitux® and led as CMO an oncology company acquired for $1.4 billion. Most recently Dr. Heeger served as CMO of a clinical-stage radiotherapy company where he advanced into global development, a PSMA program directly relevant to Actinium's ATNM-400 asset. His appointment comes at a pivotal moment as Actinium prepares to advance Actimab-A, ATNM-400, and Iomab-ACT toward key data readouts and expanded clinical trials in the second half of 2026.
"Steffen's background is uniquely suited to unlock the value in Actinium's pipeline" said Sandesh Seth, Chairman and Chief Executive Officer of Actinium Pharmaceuticals. "He has successfully taken multiple targeted oncology and radiotherapy programs from the lab into patients, including anti-PSMA programs directly relevant to our ATNM-400 asset, and has deep experience navigating global regulatory pathways with the FDA and international agencies. Steffen brings precisely the combination of deep radiotherapy expertise, global oncology clinical development leadership, regulatory experience, and executional intensity that we need as we advance and expand our pipeline of targeted radiotherapies."
"Importantly, Steffen's experience spans both hematologic malignancies and solid tumors, aligning exceptionally well with our strategic focus of building Actinium into a leading targeted radiotherapy company." Mr. Seth added. "His direct experience with alpha-emitting radiotherapies, translational medicine, and global clinical execution will be highly valuable as we progress our clinical programs and pursue new opportunities to unlock the full potential of our platform. Few clinical leaders know radiotherapy development as deeply as Steffen does, and fewer still pair that with the public-company experience and translational oncology track record he brings. We are thrilled to welcome him to Actinium."
Prior to Actinium, Dr. Heeger served as Chief Medical Officer of Full-Life Technologies, where he led global development, regulatory affairs, clinical operations, translational research, CMC, quality assurance, and program management for the company's radiotherapy pipeline. There he led the translation of three targeted radioconjugate compounds — including an anti-PSMA program in metastatic castration-resistant prostate cancer — from preclinical to clinical stage within two years, securing IND clearance and fast track designation. Prior to Full-Life, he was CMO of Pega-One, a clinical-stage oncology company that became part of Centessa Pharmaceuticals (Nasdaq: CNTA) ahead of its $380 million initial public offering. Earlier, he served as CMO of NBE-Therapeutics, where he led the IND submission and initial clinical trial of NBE-002, a first-in-class immune-stimulatory antibody-drug conjugate targeting ROR1 in triple-negative breast cancer, non-small cell lung cancer, and sarcoma. NBE-Therapeutics was subsequently acquired by Boehringer Ingelheim for $1.4 billion. Before NBE, Dr. Heeger was CMO of Selvita S.A. (WSE: SLV), where he advanced the company's lead anti-cancer compound through IND and into its first clinical trial.
Earlier in his career, Dr. Heeger served as Vice President, Head of Clinical Development at MorphoSys AG, where he led the clinical strategy and execution of the company's lead hematology and oncology programs, including monoclonal antibody therapeutics targeting CD19, CD38, and PSMA. He began his pharmaceutical career at Merck KGaA, where over nearly a decade, he led global clinical development and life cycle management for Erbitux® (cetuximab) across colorectal, head and neck, gastric, and lung cancers in major markets including the US, Europe, Japan, and China enabling its blockbuster status.
"Actinium is developing what I believe is one of the most compelling radiotherapy pipelines today." said Dr. Heeger. "Their biology-driven R&D has yielded several highly differentiated, even unique, assets that offer real opportunity to bring transformative therapies to patients with limited options. Their assets have nothing comparable being developed and each has blockbuster potential; ATNM-400 with its novel target and compelling data across the largest solid tumor indications, Actimab-A's promise to resensitize immune checkpoint inhibitors in solid tumors and backbone potential in hematological malignancies, as well as their cell and gene therapy conditioning agent Iomab-ACT. These are exactly the kinds of assets I have spent my career developing. I am honored to join Actinium at this pivotal stage and look forward to working closely with Sandesh and our team to unlock the value in our clinical programs."
Dr. Heeger holds an MD and a Master of Healthcare Management (MSc) from the University of Heidelberg, Germany, a world-leading institution for research in nuclear medicine and targeted radionuclide therapies. He trained as a clinical oncologist at the University Hospital Heidelberg, Department of Haematology and Oncology, and at the German Cancer Research Center. He has authored and co-authored more than 20 peer-reviewed publications across oncology and radiopharmaceutical research. Notably, Dr. Heeger's scientific roots include early work in alpha-radiotherapy, including published research involving alpha-radioimmunotherapy using antibody conjugates in hematologic malignancies which bring him to a full cycle at Actinium.
About Actinium Pharmaceuticals, Inc.
Actinium is a pioneer in targeted radiotherapies designed to improve outcomes for patients with cancer. The company employs a biology-driven approach to develop differentiated radiopharmaceuticals for solid tumors and hematologic malignancies. Its mission is to transform cancer treatment through innovative radioconjugates that maximize therapeutic efficacy while minimizing toxicity to healthy tissue by combining expertise in tumor biology, translational medicine, and radiochemistry. Since inception, Actinium has focused on developing innovative radiotherapies. Its pipeline reflects this strategy across three areas: (1) solid tumor therapeutics including ATNM-400 and Actimab-A with pan-tumor potential; (2) Actimab-A as a therapeutic backbone for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in collaboration with the National Cancer Institute (NCI); and (3) targeted conditioning agents including Iomab-B for bone marrow transplant and Iomab-ACT for cell and gene therapy conditioning. ATNM-400 targets a novel antigen distinct from PSMA and has demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Actimab-A has shown improved survival in relapsed/refractory AML with CLAG-M and is advancing toward a Phase 2/3 trial, with additional development ongoing through a CRADA with the NCI. Actinium is also advancing preclinical solid tumor programs and holds ~250 patents and patent applications, including intellectual property related to cyclotron-based production of Ac-225. For more information, please visit www.actiniumpharma.com.
Forward-Looking Statements
This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements, including statements as related to regaining compliance with the rules of the NYSE American and submission of a compliance plan, are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.
